Physician profile
Nazmul Hoque
NPI 1740280429
$1,356.71
in general payments reported to CMS, 2019-2025
24 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $114 · 2023: $112 · 2024: $131 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.99 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.61 | 2019-2020 | |
| Janssen Biotech, INC. | $141.29 | 2019-2023 | Stelara |
| Shionogi INC | $118.99 | 2019 | |
| Genzyme Corporation | $91.20 | 2023-2025 | |
| Novo Nordisk INC | $90.46 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $86.17 | 2019-2020 | |
| Amgen INC. | $59.15 | 2019 | |
| Glaxosmithkline, LLC. | $58.72 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $53.03 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.16 | 2019-2024 | Xifaxan |
| Pfizer INC. | $39.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.30 | 2019 | |
| Lilly USA, LLC | $35.62 | 2025 | Kisunla, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $34.61 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.33 | 2025 | Eohilia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.09 | 2024 | Jardiance |
| Exact Sciences Corporation | $23.01 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $21.65 | 2024 | Auvelity |
| Ascendis Pharma Endocrinology INC | $19.46 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $19.18 | 2019 | |
| Philips North America LLC | $16.52 | 2019 | |
| Merck Sharp & Dohme LLC | $16.05 | 2019 | |
| Amarin Pharma, INC. | $12.59 | 2020 | |
| Ucb, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazmul Hoque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.